Physician profile
Marilyn Mennig
NPI 1043222458
$2,917.04
in general payments reported to CMS, 2019-2025
15 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 96% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.39 · 2022: $573 · 2023: $604 · 2024: $461 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $470.52 | 2022-2025 | Dojolvi |
| Edwards Lifesciences Corporation | $311.80 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbvie INC. | $286.92 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $251.63 | 2023-2025 | Austedo Xr, Uzedy |
| Argenx US, INC. | $241.46 | 2023-2024 | Vyvgart |
| Axsome Therapeutics, INC. | $241.20 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $182.23 | 2025 | |
| Gilead Sciences, INC. | $136.85 | 2025 | Yeztugo |
| Alnylam Pharmaceuticals INC. | $125.00 | 2024 | Onpattro |
| Lucid Diagnostics INC. | $124.59 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $119.76 | 2022 | |
| Amgen INC. | $117.45 | 2025 | Krystexxa |
| Sage Therapeutics, LLC | $112.62 | 2023 | |
| Neurocrine Biosciences, INC. | $109.89 | 2024 | Ingrezza |
| Janssen Scientific Affairs, LLC | $85.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Mennig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.